The George Washington Cancer Institute | Strategic Alliance Partners

July 21, 2021

Mitchell R. Smith, MD, PhD, discusses the results of the ECOG-ACRIN E1411 trial examining BR-based induction treatment in patients with mantle cell lymphoma and next steps for research.

July 16, 2021

Mitchell R. Smith, MD, PhD, discusses the rationale for the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

June 09, 2021

Mitchell R. Smith, MD, PhD, discusses the results of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

December 10, 2019

Mitchell R. Smith, MD, PhD, discusses the rationale behind the trial looking at the fixed duration of the ibrutinib and venetoclax combination in chronic lymphocytic leukemia.

November 02, 2019

Mitchell R. Smith, MD, PhD, division director, Cancer and Blood Disorders, and professor of medicine, GW Cancer Center, discusses the use of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

November 01, 2019

Imad Tabbara, MD, discusses available treatment options for transplant-eligible and -ineligible patients with multiple myeloma.

October 24, 2019

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

October 17, 2019

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia.

October 09, 2019

Kieron Dunleavy, MD, discusses emerging treatment options and when to use the watch-and-wait approach in follicular lymphoma.

October 08, 2019

Eduardo Sotomayor, MD, discusses the evolution of CAR T-cell therapy, adverse events that require careful monitoring, and novel strategies under development that may mitigate toxicity and improve T-cell persistence.

October 07, 2019

Mitchell R. Smith, MD, PhD, discusses the use of chemotherapy versus targeted therapy in patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

October 04, 2019

Mitchell R. Smith, MD, PhD, discusses the potential advantage of lenalidomide in chronic lymphocytic leukemia.

October 04, 2019

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses the durability of CAR T cells, as well as ways to combat immune escape mechanisms in hematologic malignancies.

September 26, 2019

Imad Tabbara, MD, discusses the expansion of treatment options for patients with acute myeloid leukemia.

September 23, 2019

Mitchell R. Smith, MD, PhD, discusses two randomized phase III trials investigating the benefit of ibrutinib-based therapies in patients with chronic lymphocytic leukemia.